NasdaqGS:DNLIBiotechs
Does Denali Therapeutics' (DNLI) Widening Quarterly Loss Reframe Its Pipeline-First Investment Narrative?
Denali Therapeutics Inc. recently reported fourth-quarter 2025 results, with a net loss of US$128.55 million, compared with US$114.75 million a year earlier, and basic and diluted loss per share from continuing operations of US$0.73 versus US$0.67.
The widening loss highlights the financial impact of Denali’s ongoing efforts to advance its pipeline, even as per-share losses increased year over year.
With these earnings revealing a larger quarterly loss, we’ll examine what this means for...